About this episode

Pamela Tenaerts discusses the limitations of human-only clinical development and the potential of agentic AI to improve clinical trials.

Send us Fan Mail The clinical trial system is starting to look like a motorway at a standstill: more and more drugs are lining up, but the lanes ahead are already full. We sit down with Pamela Tenart to unpack why the industry may have reached the limit of human-only clinical development, and why “adding more people” is no longer a realistic plan when experienced CRAs, site co-ordinators and trial operators are already stretched thin. From there, we get practical about what agentic AI could ...

Explore listener stats, chart rankings, contacts and more on the Lab to Lives podcast page.